March 20th 2020
David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.
Terence T. Sio, MD, MS, discusses the utility of proton therapy in lung cancer.
March 18th 2020
Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.
Anastasios Dimou, MD, discusses available and emerging treatment options and approaches for patients with oncogenic-driven lung cancer.
March 17th 2020
Neeta Somaiah, MD, discusses ongoing research in the field of sarcoma.
Jonathan C. Trent, MD, PhD, discusses recent advances and ongoing research in the field of soft tissue sarcoma.
March 16th 2020
Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR, discusses the findings of the retrospective analysis of pulmonary hypertension in patients with myelofibrosis and their impact on clinical practice.
March 11th 2020
Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.
March 10th 2020
Matthew H.G. Katz, MD, FACS, discusses data with neoadjuvant therapy and ongoing research in pancreatic cancer.
March 9th 2020
Mohammad Maher Abdul-Hay, MD, discusses current standards for the treatment of patients with acute lymphocytic leukemia.
Gareth J. Morgan, MD, PhD, discusses ongoing research of BCMA-targeted therapies, as well as the use of venetoclax in the myeloma treatment paradigm.
March 7th 2020
March 5th 2020
Faith E. Davies, MD, discusses pivotal research in relapsed/refractory myeloma and precision medicine efforts in the field.
March 4th 2020
Michael L. Grossbard, MD, discusses recent changes to the follicular lymphoma paradigm and therapeutic approaches on the horizon.
Shella Saint Fleur-Lominy, MD, PhD, discusses some of the current and investigational treatment options for patients with myeloproliferative neoplasms.
Jonathan W. Goldman, MD, discusses the current landscape of biomarker-driven lung cancer.
March 3rd 2020
James Weitzman, MD, discusses progress in the multiple myeloma treatment paradigm and what challenges remain.
Michael K. Gould, MD, MS, discusses pivotal lung cancer screening trials and their impact on clinical practice.
February 27th 2020
Andrew Branagan, MD, discusses the evolving role of transplant and ongoing research in high-risk multiple myeloma.
Ian S. Hagemann, MD, PhD, discusses identifying resectable lymph nodes via ultrastaging and the importance of multidisciplinary treatment in patients with endometrial cancer.